Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 4, 2026
- ADMA Biologics reported 3Q 2026 total revenue of $141.1 million, up 5% year-over-year, and GAAP net income of $49.9 million, up 37%; it reiterated FY2026 revenue guidance of at least $530 million while increasing adjusted earnings expectations.
- 10-Q report · filed Nov 4, 2026
- ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands.
The audio replay and transcript follow the call.